# Nanolattix

Source: https://onco.cc/companies/nanolattix/  
OnCo record `nanolattix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nanolattix develops antibody-drug conjugates, which carry a cancer drug to tumour cells, and radioactive versions for scanning and treatment. Its lead medicine, T320, targets tissue factor, a protein found on many solid tumours, and is in early trials in China.

## Summary

Nanolattix, the English name of Shanxi Naan Biological Technology Co., Ltd. (纳安生物), is based in the Shanxi Transformation and Comprehensive Reform Demonstration Zone in Taiyuan, China, and was established in 2016 by Zhican Qu, according to the company. The group also runs a separate health business making plant extracts, cosmetics and related consumer products. Its BioLattix platform supports more than ten ADC and radionuclide drug conjugate (RDC) programmes using monoclonal, bispecific and nanobody antibodies. The lead product, T320-ADC, an anti-tissue factor antibody-drug conjugate aimed at cervical, ovarian, non-small cell lung and other solid tumours, has IND clearance from China's NMPA, the US FDA and Australia's TGA and FDA orphan drug designation for pancreatic cancer, according to the company, and is in trials with the Cancer Hospital of the Chinese Academy of Medical Sciences and other centres. The company also runs an early study of RT01-89Zr, a zirconium-89 PET imaging agent, in solid tumours (NCT07505069). Its first registered cancer trial, NCT07434609, a phase 1 study of T320 in advanced solid tumours, was posted on ClinicalTrials.gov in February 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Nanolattix Biotechnology Co., Ltd.; Shanxi Naan Biological Technology Co., Ltd.; 山西纳安生物科技股份有限公司; 纳安生物
- HQ: Taiyuan
- Type: biotech
- Website: https://www.naanjt.com/

## Notes

- The registry contact domain is jiangnan.edu.cn (Jiangnan University); the company website was found at naanjt.com, whose English version uses the name Nanolattix.
- The company also sells consumer health products, including cosmetics; only its oncology drug work is described here.
- The target of RT01-89Zr is not stated in the registry title read.
- No financing round was read; none is recorded.
- Company website (Chinese and English) read on 29 October 2026.

## Sources

- Official website: https://www.naanjt.com/
- English website: http://en.naanjt.com/
- ClinicalTrials.gov: phase 1 study of T320 anti-tissue factor ADC (NCT07434609): https://clinicaltrials.gov/study/NCT07434609
- ClinicalTrials.gov: early study of RT01-89Zr PET imaging in solid tumours (NCT07505069): https://clinicaltrials.gov/study/NCT07505069

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Imaging](https://onco.cc/fronts/imaging/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immuno-PET](https://onco.cc/technologies/immuno-pet/)
- targets: [Tissue factor](https://onco.cc/targets/tissue-factor/)

---
JSON: https://onco.cc/api/v1/entities/nanolattix.json